The tumor immune microenvironment in pancreatic cancer and its potential in the identification of immunotherapy biomarkers

ABSTRACT Introduction Pancreatic cancer (PC) has an extremely poor prognosis, even with surgical resection and triplet chemotherapy treatment. Cancer immunotherapy has been recently approved for tumor-agnostic treatment with genome analysis, including in PC. However, it has limited efficacy. Areas covered In addition to the low tumor mutation burden, one of the difficulties of immunotherapy in PC is the presence of abundant stromal cells in its microenvironment. Among stromal cells, cancer-associated fibroblasts (CAFs) play a major role in immunotherapy resistance, and CAF-targeted therapies are currently under development, including those in combination with immunotherapies. Meanwhile, microbiomes and tumor-derived exosomes (TDEs) have been shown to alter the behavior of distant receptor cells in PC. This review discusses the role of CAFs, microbiomes, and TDEs in PC tumor immunity. Expert opinion Elucidating the mechanisms by which CAFs, microbiomes, and TDEs are involved in the tumorigenesis of PC will be helpful for developing novel immunotherapeutic strategies and identifying companion biomarkers for immunotherapy. Spatial single-cell analysis of the tumor microenvironment will be useful for identifying biomarkers of PC immunity. Furthermore, given the complexity of immune mechanisms, artificial intelligence models will be beneficial for predicting the efficacy of immunotherapy.

[1]  M. Sho,et al.  Essential updates 2021/2022: Surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma , 2023, Annals of gastroenterological surgery.

[2]  Y. Hamamoto,et al.  Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity , 2022, Cancer medicine.

[3]  Jufang Wang,et al.  Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma , 2022, Cell Death & Disease.

[4]  Maryam Feghhi,et al.  The distinct roles of exosomes in innate immune responses and therapeutic applications in cancer. , 2022, European journal of pharmacology.

[5]  R. Kurzrock,et al.  Clinical trial design in the era of precision medicine , 2022, Genome medicine.

[6]  Ryouichi Tsunedomi,et al.  Immune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer Cells , 2022, Annals of Surgical Oncology.

[7]  F. Motoi,et al.  Levels of tumor markers CEA/CA 19–9 in serum and peritoneal lavage predict postoperative recurrence in patients with pancreatic cancer , 2022, Annals of gastroenterological surgery.

[8]  Kongming Wu,et al.  Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer , 2022, Frontiers in Immunology.

[9]  H. Nagano,et al.  Elevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cells , 2022, BMC cancer.

[10]  Wasiu A. Akanni,et al.  A faecal microbiota signature with high specificity for pancreatic cancer , 2022, Gut.

[11]  M. Akbari,et al.  Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy , 2022, Molecular cancer.

[12]  V. Dudeja,et al.  Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting , 2021, International journal of molecular sciences.

[13]  Tahereh Etemadi,et al.  Tumor-derived extracellular vesicles: The metastatic organotropism drivers. , 2021, Life sciences.

[14]  J. Sicklick,et al.  Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study , 2021, Genome medicine.

[15]  B. Helmink,et al.  Hallmarks of response, resistance, and toxicity to immune checkpoint blockade , 2021, Cell.

[16]  H. V. van Laarhoven,et al.  The Cellular Origins of Cancer-Associated Fibroblasts and Their Opposing Contributions to Pancreatic Cancer Growth , 2021, Frontiers in Cell and Developmental Biology.

[17]  P. Prathipati,et al.  New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[18]  H. An,et al.  Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors , 2021, International journal of molecular sciences.

[19]  Z. Shao,et al.  Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence , 2021, Signal Transduction and Targeted Therapy.

[20]  L. Zitvogel,et al.  Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology? , 2021, Cancer discovery.

[21]  M. Brocchi,et al.  Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics , 2021, Bioactive materials.

[22]  C. Jean,et al.  Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy? , 2021, Cancers.

[23]  M. Akbari,et al.  The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells , 2021, Molecular cancer.

[24]  Xiao Luo,et al.  Tumor-derived exosomal components: the multifaceted roles and mechanisms in breast cancer metastasis , 2021, Cell Death & Disease.

[25]  D. Wirtz,et al.  Extracellular vesicles in immunomodulation and tumor progression , 2021, Nature Immunology.

[26]  Y. Yarden,et al.  The key roles of cancer stem cell-derived extracellular vesicles , 2021, Signal Transduction and Targeted Therapy.

[27]  R. Ramesh,et al.  Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy , 2021, The AAPS Journal.

[28]  J. Badger,et al.  Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients , 2021, Science.

[29]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[30]  D. Wainwright,et al.  NK cell-based cancer immunotherapy: from basic biology to clinical development , 2021, Journal of Hematology & Oncology.

[31]  Chuanzhao Zhang,et al.  Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1 , 2021, Journal for ImmunoTherapy of Cancer.

[32]  P. Wei,et al.  Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma , 2021, Oncoimmunology.

[33]  Lucas Ferrari de Andrade,et al.  NKG2D and MICA/B shedding: a ‘tag game’ between NK cells and malignant cells , 2020, Clinical & translational immunology.

[34]  N. Ajami,et al.  Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients , 2020, Science.

[35]  P. Gibbs,et al.  Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. , 2020, The New England journal of medicine.

[36]  B. Dong,et al.  The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction , 2020, International journal of cancer.

[37]  Xiaofang Wang,et al.  Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients , 2020, Journal of Nanobiotechnology.

[38]  Shu Guo,et al.  Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies , 2020, Frontiers in Cell and Developmental Biology.

[39]  J. Sicklick,et al.  Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy , 2020, Nature Communications.

[40]  Jianjun Zhang,et al.  Oral cancer cell-derived exosomes modulate natural killer cell activity by regulating the receptors on these cells , 2020, International journal of molecular medicine.

[41]  A. Möller,et al.  The evolving translational potential of small extracellular vesicles in cancer , 2020, Nature Reviews Cancer.

[42]  T. Oda,et al.  Adipose‐derived mesenchymal stem cells differentiate into pancreatic cancer‐associated fibroblasts in vitro , 2020, FEBS open bio.

[43]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[44]  J. Ju,et al.  Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions , 2020, Scientific Reports.

[45]  Z. Shao,et al.  Natural killer cells in cancer biology and therapy , 2020, Molecular Cancer.

[46]  Y. Tao,et al.  Exosomes: key players in cancer and potential therapeutic strategy , 2020, Signal Transduction and Targeted Therapy.

[47]  R. Rahbarghazi,et al.  Exosomal cargos modulate autophagy in recipient cells via different signaling pathways , 2020, Cell & Bioscience.

[48]  M. Oren,et al.  The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic , 2020, Nature.

[49]  Joon-Oh Park,et al.  Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Yong Li,et al.  A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications , 2020, Frontiers in Immunology.

[51]  E. Buzás,et al.  Fibroblast-Derived Extracellular Vesicles Induce Colorectal Cancer Progression by Transmitting Amphiregulin , 2020, Frontiers in Cell and Developmental Biology.

[52]  G. de Pouvourville,et al.  Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective , 2020, Journal for ImmunoTherapy of Cancer.

[53]  Jun Yan,et al.  Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy. , 2020, Trends in cancer.

[54]  Joseph Cursons,et al.  The cancer–natural killer cell immunity cycle , 2020, Nature Reviews Cancer.

[55]  Shuai Jiang,et al.  Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle. , 2020, Trends in cancer.

[56]  J. Wolchok,et al.  The future of cancer immunotherapy: microenvironment-targeting combinations , 2020, Cell Research.

[57]  Stephen M. Shaw,et al.  BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial , 2020, Nature Medicine.

[58]  W. Olejarz,et al.  Tumor-Derived Exosomes in Immunosuppression and Immunotherapy , 2020, Journal of immunology research.

[59]  E. Elinav,et al.  Interaction between microbiota and immunity in health and disease , 2020, Cell Research.

[60]  T. Whiteside,et al.  Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes , 2020, Neuro-oncology advances.

[61]  L. Wood,et al.  Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications , 2020, Gut.

[62]  J. Szabó,et al.  Oncobiosis and Microbial Metabolite Signaling in Pancreatic Adenocarcinoma , 2020, Cancers.

[63]  Z. Zeng,et al.  The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer , 2020, Frontiers in Immunology.

[64]  R. Greil,et al.  Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence , 2020, International journal of molecular sciences.

[65]  Charles H. Yoon,et al.  Inhibition of MICA and MICB Shedding Elicits NK-Cell–Mediated Immunity against Tumors Resistant to Cytotoxic T Cells , 2020, Cancer Immunology Research.

[66]  Yuanting Gu,et al.  Cancer-associated fibroblasts-derived exosomes suppresses immune cell function in breast cancer via miR-92/PD-L1 pathway , 2020 .

[67]  R. Ramesh,et al.  Progress in extracellular vesicle biology and their application in cancer medicine , 2020, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[68]  Xinmei Yu,et al.  Predicting treatment response of patients with extranodal natural killer/T‐cell lymphoma based on levels of PD‐L1 mRNA and soluble PD‐L1 , 2020, Hematological oncology.

[69]  R. Rahbarghazi,et al.  Autophagy modulation altered differentiation capacity of CD146+ cells toward endothelial cells, pericytes, and cardiomyocytes , 2020, Stem Cell Research & Therapy.

[70]  Raghu Kalluri,et al.  The biology, function, and biomedical applications of exosomes , 2020, Science.

[71]  I. Kocherova,et al.  Inclusion Biogenesis, Methods of Isolation and Clinical Application of Human Cellular Exosomes , 2020, Journal of clinical medicine.

[72]  K. Leroy,et al.  Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study , 2020, Cancers.

[73]  Z. Zeng,et al.  Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy , 2020, Molecular Cancer.

[74]  G. Freeman,et al.  The importance of exosomal PDL1 in tumour immune evasion , 2020, Nature Reviews Immunology.

[75]  J. Kirkwood,et al.  Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells , 2020, Scientific Reports.

[76]  C. Garrido,et al.  Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients , 2020, Journal of extracellular vesicles.

[77]  P. Hegde,et al.  Top 10 Challenges in Cancer Immunotherapy. , 2020, Immunity.

[78]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  V. Vignard,et al.  MicroRNAs in Tumor Exosomes Drive Immune Escape in Melanoma , 2019, Cancer Immunology Research.

[80]  I. Jacobs,et al.  Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? , 2019, Journal of Immunotherapy for Cancer.

[81]  T. Lv,et al.  Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients , 2019, Journal of Translational Medicine.

[82]  V. Patel,et al.  The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[83]  N. Cacalano,et al.  Exosomes: Versatile Nano Mediators of Immune Regulation , 2019, Cancers.

[84]  Myung Ah Lee,et al.  Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[85]  S. Pushalkar,et al.  The Fungal Mycobiome Promotes Pancreatic Oncogenesis via MBL Activation , 2019, Nature.

[86]  Siwei Wang,et al.  Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy , 2019, Journal of Hematology & Oncology.

[87]  H. Nagano,et al.  Novel Biomarkers for Personalized Cancer Immunotherapy , 2019, Cancers.

[88]  Christine B. Peterson,et al.  Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes , 2019, Cell.

[89]  Jae Cheol Lee,et al.  Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer , 2019, Experimental & Molecular Medicine.

[90]  P. Robson,et al.  Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. , 2019, Cancer discovery.

[91]  A. Addeo,et al.  The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy , 2019, Front. Med..

[92]  C. Pilarsky,et al.  c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer , 2019, International journal of molecular sciences.

[93]  Kelvin K. W. Chan,et al.  Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non–Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale , 2019, JAMA network open.

[94]  T. Whiteside,et al.  Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. , 2019, Carcinogenesis.

[95]  K. Yamaguchi,et al.  Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy , 2019, Cancer science.

[96]  J. Qin,et al.  Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer , 2019, Cancers.

[97]  Peifeng Li,et al.  Emerging Function and Clinical Values of Exosomal MicroRNAs in Cancer , 2019, Molecular therapy. Nucleic acids.

[98]  Geeta Mehta,et al.  Integrated cancer tissue engineering models for precision medicine , 2019, PloS one.

[99]  Bin Li,et al.  Applications of machine learning in drug discovery and development , 2019, Nature Reviews Drug Discovery.

[100]  A. Aref,et al.  Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance , 2019, Molecular Cancer.

[101]  R. Blelloch,et al.  Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory , 2019, Cell.

[102]  Muhammad Qasim,et al.  Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes , 2019, Cells.

[103]  É. Vivier,et al.  Targeting natural killer cells in solid tumors , 2019, Cellular & Molecular Immunology.

[104]  B. Helmink,et al.  The microbiome, cancer, and cancer therapy , 2019, Nature Medicine.

[105]  Jing Zhao,et al.  Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel , 2019, JAMA oncology.

[106]  J. Sicklick,et al.  Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study , 2019, Nature Medicine.

[107]  Zhigui Li,et al.  PD‐1/PD‐L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway , 2019, Cell proliferation.

[108]  Z. Zeng,et al.  Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape , 2019, Molecular Cancer.

[109]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[110]  I. Endo,et al.  Role of the tumor microenvironment in pancreatic cancer , 2019, Annals of gastroenterological surgery.

[111]  Lingling Wu,et al.  Exosomal PD-L1: an effective liquid biopsy target to predict immunotherapy response , 2018, National science review.

[112]  S. M. Toor,et al.  Immune checkpoint inhibitors: recent progress and potential biomarkers , 2018, Experimental & Molecular Medicine.

[113]  Xiang Xu,et al.  Soluble immune checkpoints in cancer: production, function and biological significance , 2018, Journal of Immunotherapy for Cancer.

[114]  B. Helmink,et al.  Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis , 2018, Nature Medicine.

[115]  J. Izard,et al.  The Microbiomes of Pancreatic and Duodenum Tissue Overlap and Are Highly Subject Specific but Differ between Pancreatic Cancer and Noncancer Subjects , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[116]  H. Nagano,et al.  Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies , 2018, Expert Review of Anticancer Therapy.

[117]  Yi Qin,et al.  The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer , 2018, Theranostics.

[118]  David W. Greening,et al.  Extracellular vesicles in cancer — implications for future improvements in cancer care , 2018, Nature Reviews Clinical Oncology.

[119]  S. Adams,et al.  Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application , 2018, Cancer Immunology Research.

[120]  N. Paragios,et al.  A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. , 2018, The Lancet. Oncology.

[121]  Jacob Silterra,et al.  Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab , 2018, Nature Medicine.

[122]  M. Teh,et al.  Transcriptome reprogramming by cancer exosomes: identification of novel molecular targets in matrix and immune modulation , 2018, Molecular Cancer.

[123]  Jie Pan,et al.  Tumor exosomes block dendritic cells maturation to decrease the T cell immune response. , 2018, Immunology letters.

[124]  M. Hung,et al.  Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth , 2018, Cell Research.

[125]  H. Nagano,et al.  Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy , 2018, Annals of gastroenterological surgery.

[126]  Wei Zhang,et al.  Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response , 2018, Nature.

[127]  Luigia Stefania Stucci,et al.  Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity , 2018, Oncotarget.

[128]  J. Wargo,et al.  The gut microbiota influences anticancer immunosurveillance and general health , 2018, Nature Reviews Clinical Oncology.

[129]  S. Pushalkar,et al.  The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. , 2018, Cancer discovery.

[130]  G. Madonna,et al.  Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma , 2018, Oncoimmunology.

[131]  Boris Sepesi,et al.  Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer , 2018, Scientific Reports.

[132]  C. Iacobuzio-Donahue,et al.  Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations , 2018, Clinical Cancer Research.

[133]  H. Eguchi,et al.  Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study , 2018, Cancer Immunology Research.

[134]  Donna Neuberg,et al.  Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer , 2017, Science.

[135]  Lei Zheng,et al.  HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  A. Sharpe,et al.  The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.

[137]  Mithat Gönen,et al.  Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer , 2017, Nature.

[138]  T. Whiteside,et al.  Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia , 2017, Scientific Reports.

[139]  E. Puré,et al.  Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma. , 2017, JCI insight.

[140]  Noam Shental,et al.  Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine , 2017, Science.

[141]  Hakho Lee,et al.  Novel nanosensing technologies for exosome detection and profiling. , 2017, Lab on a chip.

[142]  Axel Benner,et al.  Tumor-derived exosomes modulate PD-L1 expression in monocytes , 2017, Science Immunology.

[143]  M. Seno,et al.  A cancer stem cell model as the point of origin of cancer-associated fibroblasts in tumor microenvironment , 2017, Scientific Reports.

[144]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[145]  Alicia Llorente,et al.  Current knowledge on exosome biogenesis and release , 2017, Cellular and Molecular Life Sciences.

[146]  M. Oka,et al.  Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy , 2017, Pancreas.

[147]  Jian Huang,et al.  Tumor-Related Exosomes Contribute to Tumor-Promoting Microenvironment: An Immunological Perspective , 2017, Journal of immunology research.

[148]  Yang Xia,et al.  Negative regulation of tumor-infiltrating NK cell in clear cell renal cell carcinoma patients through the exosomal pathway , 2017, Oncotarget.

[149]  P. Worley,et al.  Orai1-Mediated Antimicrobial Secretion from Pancreatic Acini Shapes the Gut Microbiome and Regulates Gut Innate Immunity. , 2017, Cell metabolism.

[150]  Hans Clevers,et al.  Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer , 2017, The Journal of experimental medicine.

[151]  D. Chia,et al.  Saliva exosomes from pancreatic tumor–bearing mice modulate NK cell phenotype and antitumor cytotoxicity , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[152]  H. Imaoka,et al.  Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients , 2017, International journal of cancer.

[153]  D. Webb,et al.  Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. , 2017, Biochemical Society transactions.

[154]  Yusuke Nakamura,et al.  Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS‐PC study , 2016, Cancer science.

[155]  R. Hayes,et al.  Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study , 2016, Gut.

[156]  J. Berlin,et al.  Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  R. Hill,et al.  CANCER-ASSOCIATED FIBROBLAST EXOSOMES REGULATE SURVIVAL AND PROLIFERATION OF PANCREATIC CANCER CELLS , 2016, Oncogene.

[158]  A. Oxenius,et al.  Recognition and Regulation of T Cells by NK Cells , 2016, Front. Immunol..

[159]  S. Hingorani,et al.  Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma. , 2016, Gastroenterology.

[160]  T. Conroy,et al.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.

[161]  J. Redzic,et al.  Glioma-derived extracellular vesicles selectively suppress immune responses. , 2016, Neuro-oncology.

[162]  R. Kalluri.  The biology and function of exosomes in cancer. , 2016, The Journal of clinical investigation.

[163]  T. Whiteside.  Exosomes and tumor-mediated immune suppression. , 2016, The Journal of clinical investigation.

[164]  L. Mincheva-Nilsson,et al.  Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity , 2016, Tumor Biology.

[165]  Y. Yonemitsu,et al.  Dendritic cell-based vaccine for pancreatic cancer in Japan. , 2016, World journal of gastrointestinal pharmacology and therapeutics.

[166]  T. Whiteside,et al.  Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer , 2016, Journal of extracellular vesicles.

[167]  Xuetao Cao,et al.  Immunosuppressive cells in tumor immune escape and metastasis , 2015, Journal of Molecular Medicine.

[168]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[169]  S. Kelley,et al.  Characterization of the salivary microbiome in patients with pancreatic cancer , 2015, PeerJ.

[170]  R. Salgia,et al.  Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[171]  M. Alenquer,et al.  Exosome Biogenesis, Regulation, and Function in Viral Infection , 2015, Viruses.

[172]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[173]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[174]  Wendy S. Garrett,et al.  Cancer and the microbiota , 2015, Science.

[175]  Koichi Hirata,et al.  Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis , 2015, Oncotarget.

[176]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[177]  C. Théry,et al.  Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. , 2014, Annual review of cell and developmental biology.

[178]  L. Mincheva-Nilsson,et al.  Prostate Tumor-Derived Exosomes Down-Regulate NKG2D Expression on Natural Killer Cells and CD8+ T Cells: Mechanism of Immune Evasion , 2014, PloS one.

[179]  Edward J. Kim,et al.  Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma , 2014, Clinical Cancer Research.

[180]  Clotilde Théry,et al.  Biogenesis and secretion of exosomes. , 2014, Current opinion in cell biology.

[181]  M. Oka,et al.  Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer , 2014, Journal of Translational Medicine.

[182]  Y. Luan,et al.  The significance and regulatory mechanisms of innate immune cells in the development of sepsis. , 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[183]  Lynda Chin,et al.  Identification of Double-stranded Genomic DNA Spanning All Chromosomes with Mutated KRAS and p53 DNA in the Serum Exosomes of Patients with Pancreatic Cancer* , 2014, The Journal of Biological Chemistry.

[184]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[185]  E. Puré,et al.  Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity , 2013, Cancer Immunology Research.

[186]  C. Dray,et al.  Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. , 2013, Cancer research.

[187]  James O. Jones,et al.  Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia , 2013, The Journal of experimental medicine.

[188]  Graça Raposo,et al.  Extracellular vesicles: Exosomes, microvesicles, and friends , 2013, The Journal of cell biology.

[189]  Hao Liu,et al.  Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[190]  T. Whiteside.  Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). , 2013, Biochemical Society transactions.

[191]  F. Clavel-Chapelon,et al.  Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study , 2012, Gut.

[192]  H. Buermans,et al.  Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions , 2012, Nucleic acids research.

[193]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[194]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[195]  V. Boussiotis,et al.  Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation , 2012, Science Signaling.

[196]  M. Plummer,et al.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. , 2012, The Lancet. Oncology.

[197]  Peter Kirkpatrick,et al.  Vismodegib , 2012, Nature reviews. Drug discovery.

[198]  Derek S. Chan,et al.  Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer , 2012, Gut.

[199]  Malini Guha.  Hedgehog inhibitor gets landmark skin cancer approval, but questions remain for wider potential , 2012, Nature Reviews Drug Discovery.

[200]  D. Chia,et al.  Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer , 2011, Gut.

[201]  Hans Clevers,et al.  Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. , 2011, Gastroenterology.

[202]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[203]  G. Getz,et al.  PathSeq: software to identify or discover microbes by deep sequencing of human tissue , 2011, Nature Biotechnology.

[204]  A. Cerwenka,et al.  Natural Killer Cells and Solid Tumors , 2011, Journal of Innate Immunity.

[205]  L. Mincheva-Nilsson,et al.  Thermal- and Oxidative Stress Causes Enhanced Release of NKG2D Ligand-Bearing Immunosuppressive Exosomes in Leukemia/Lymphoma T and B Cells , 2011, PloS one.

[206]  R. Jain,et al.  Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors , 2011, Proceedings of the National Academy of Sciences.

[207]  E. Giannoni,et al.  Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. , 2010, Cancer research.

[208]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[209]  Samit R. Joshi,et al.  Aging of the innate immune system. , 2010, Current opinion in immunology.

[210]  Qiang Zhou,et al.  Cellular Internalization of Exosomes Occurs Through Phagocytosis , 2010, Traffic.

[211]  J. Skepper,et al.  Differential Mechanisms of Shedding of the Glycosylphosphatidylinositol (GPI)-anchored NKG2D Ligands* , 2010, The Journal of Biological Chemistry.

[212]  J. Skepper,et al.  Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. , 2010, Cancer research.

[213]  Masafumi Nakamura,et al.  Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway , 2009, Journal of surgical oncology.

[214]  Raoul Tibes,et al.  Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. , 2009, The New England journal of medicine.

[215]  Gerald C. Chu,et al.  Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. , 2009, Cancer cell.

[216]  Thomas G. Caffery,et al.  Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer , 2008, Clinical Cancer Research.

[217]  M. Sayegh,et al.  Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells , 2008, Proceedings of the National Academy of Sciences.

[218]  M. Mason,et al.  Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression1 , 2008, The Journal of Immunology.

[219]  David Goldstein,et al.  Pancreatic stellate cells: partners in crime with pancreatic cancer cells. , 2008, Cancer research.

[220]  D. Hanahan,et al.  Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting , 2008, PLoS medicine.

[221]  Liang Xie,et al.  Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. , 2007, Cancer research.

[222]  U. Stenram,et al.  Helicobacter species ribosomal DNA in the pancreas, stomach and duodenum of pancreatic cancer patients. , 2006, World journal of gastroenterology.

[223]  A. Clayton,et al.  Exosomes and the MICA-NKG2D system in cancer. , 2005, Blood cells, molecules & diseases.

[224]  M. Blaser,et al.  Tooth loss, pancreatic cancer, and Helicobacter pylori. , 2003, The American journal of clinical nutrition.

[225]  P. Dalerba,et al.  Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction , 2002, Immunological reviews.

[226]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[227]  A. Theocharis,et al.  Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. , 2000, Biochimica et biophysica acta.

[228]  C. Melief,et al.  B lymphocytes secrete antigen-presenting vesicles , 1996, The Journal of experimental medicine.

[229]  OUP accepted manuscript , 2022, The Oncologist.

[230]  K. Tamada,et al.  Cancer Immunotherapy Targeting Co-signal Molecules. , 2019, Advances in experimental medicine and biology.

[231]  L. Conti,et al.  Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source. , 2019, Progress in molecular biology and translational science.